Soligenix Inc. Common Stock (SNGX)

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cu…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

13

Website

www.soligenix.com/

Fundamentals

1-day range

$0.3748$0.39

Market cap

$8.22M

P/E (trailing)

—

P/E (forward)

-1.51

EPS (trailing)

$-1.97

Dividend yield

—

Beta

2.09

Avg. volume

987.8K

Dividend pay date

October 7, 2016

Forecasts

2 analyst ratings

Soligenix Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SNGX

  Soligenix Inc. Common Stock

  $0.38

  ▲ 0.00%
  Market cap $8.22MP/E —
  $0.28$3.22
• CNSP

  CNS Pharmaceuticals Inc. Common Stock

  $5.52

  ▲ 0.11%
  Market cap $8.46MP/E —
  $1.9$10.59
• ADIL

  Adial Pharmaceuticals Inc Common Stock

  $5.6

  ▼ 1.41%
  Market cap $7.80MP/E —
  $1.31$249.81
• MTVA

  MetaVia Inc. Common Stock

  $1.71

  ▲ 3.01%
  Market cap $7.64MP/E —
  $0.9661$19.03
• APRE

  Aprea Therapeutics Inc. Common stock

  $0.8387

  ▼ 2.48%
  Market cap $7.40MP/E —
  $0.548$1.69
• APUS

  Apimeds Pharmaceuticals US Inc. Common Stock

  $3.87

  ▼ 1.28%
  Market cap $7.32MP/E —
  $3.39$403.1
• TRAW

  Traws Pharma Inc. Common Stock

  $0.59

  ▲ 0.00%
  Market cap $7.18MP/E —
  $0.4301$3.27

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Soligenix Q2 EPS $(0.12) Beats $(0.15) Estimate
  Benzinga · 8/7/2026

Institutional Ownership

March 31, 2026

Total shares held

206.4K

Total value held

$243.5K

Institutional holders

13